Difference between revisions of "Waldenström macroglobulinemia - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "|Phase II" to "|Phase 2")
Line 89: Line 89:
 
<!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] -->
 
<!-- # '''Abstract:''' Furman, Richard R., Eradat, Herbert, DiRienzo, Christine Gabriella, Hayman, Suzanne R, Hofmeister, Craig C., Avignon, Nathalie A., Leonard, John P., Coleman, Morton, Advani, Ranjana, Switzky, Julie C., Liao, Qiming, Shah, Damini N., Lisby, Steen, Lin, Thomas S. A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. Blood 2011 118:3701 [http://www.bloodjournal.org/content/118/21/3701.abstract link to abstract] -->
 
# '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971 PubMed] NCT00811733
 
# '''GSK 110921:''' Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30166-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484580/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27914971 PubMed] NCT00811733
 +
 +
==Panobinostat monotherapy {{#subobject:f079ae|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:2221fe|Variant=1}}===
 +
{| class="wikitable" style="width: 40%; text-align:center;"
 +
!style="width: 25%"|Study
 +
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578951/ Ghobrial et al. 2013 (DFCI 09-071)]
 +
|style="background-color:#91cf61"|Phase 2
 +
|-
 +
|}
 +
====Targeted therapy====
 +
*[[Panobinostat (Farydak)]] 30 mg PO 3 days per week (Mondays, Wednesdays, and Fridays)
 +
 +
'''28-day cycles'''
 +
 +
===References===
 +
# '''DFCI 09-071:''' Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303. Epub 2013 Jan 3. [http://www.bloodjournal.org/content/121/8/1296.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578951/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23287861 PubMed] NCT00936611
  
 
[[Category:Waldenström macroglobulinemia regimens]]
 
[[Category:Waldenström macroglobulinemia regimens]]

Revision as of 01:15, 20 May 2022

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main WM regimen page to find other regimens.

3 regimens on this page
5 variants on this page


First-line therapy

Ofatumumab monotherapy

back to top

Regimen variant #1

Study Evidence
Furman et al. 2016 (GSK 110921) Phase 2

Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.

Targeted therapy

4-week course

Regimen variant #2

Study Evidence
Furman et al. 2016 (GSK 110921) Phase 2

Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.

Targeted therapy

5-week course

References

  1. GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains protocol link to PMC article PubMed NCT00811733

Relapsed or refractory

Ofatumumab monotherapy

back to top

Regimen variant #1

Study Evidence
Furman et al. 2016 (GSK 110921) Phase 2

Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.

Targeted therapy

4-week course

Regimen variant #2

Study Evidence
Furman et al. 2016 (GSK 110921) Phase 2

Note: This study used two dosing schemas, based on a mid-study amendment. See paper for details about redosing based on response. It is not clear from the abstract how many patients were untreated versus relapsed. As of 10/15/2020, ofatumumab is no longer available for commercial purchase and is not being made available for this indication.

Targeted therapy

5-week course

References

  1. GSK 110921: Furman RR, Eradat HA, DiRienzo CG, Hofmeister CC, Hayman SR, Leonard JP, Coleman M, Advani R, Chanan-Khan A, Switzky J, Liao QM, Shah D, Jewell RC, Lisby S, Lin TS. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24-e34. Epub 2016 Nov 30. link to original article contains protocol link to PMC article PubMed NCT00811733

Panobinostat monotherapy

back to top

Regimen

Study Evidence
Ghobrial et al. 2013 (DFCI 09-071) Phase 2

Targeted therapy

28-day cycles

References

  1. DFCI 09-071: Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303. Epub 2013 Jan 3. link to original article contains verified protocol link to PMC article PubMed NCT00936611
Retrieved from "https://hemonc.org/w/index.php?title=Waldenström_macroglobulinemia_-_historical&oldid=56447"